Tarsus Pharmaceuticals Inc
TARS55.000USD
+0.975+1.80%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
2.32BMarket Cap
LossP/E TTM
More Details of Tarsus Pharmaceuticals Inc Company
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Company Info
Ticker SymbolTARS
Company nameTarsus Pharmaceuticals Inc
IPO dateOct 16, 2020
CEOMr. Bobak (Bobby) Azamian, M.D., Ph.D.
Number of employees323
Security typeOrdinary Share
Fiscal year-endOct 16
Address15440 Laguna Canyon Road
CityIRVINE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92618
Phone19494099820
Websitehttps://www.tarsusrx.com/
Ticker SymbolTARS
IPO dateOct 16, 2020
CEOMr. Bobak (Bobby) Azamian, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
151.78K
-16.10%
Dr. Seshadri Neervannan, Ph.D.
Dr. Seshadri Neervannan, Ph.D.
Chief Operating Officer
Chief Operating Officer
79.68K
+23.03%
Dr. Bryan Wahl, M.D., J.D.
Dr. Bryan Wahl, M.D., J.D.
General Counsel, Secretary
General Counsel, Secretary
49.09K
+24.08%
Mr. Aziz Mottiwala
Mr. Aziz Mottiwala
Chief Commercial Officer
Chief Commercial Officer
47.56K
-26.90%
Ms. Dianne C. Whitfield
Ms. Dianne C. Whitfield
Chief Human Resources Officer
Chief Human Resources Officer
44.38K
+37.80%
Mr. Jeffrey S. (Jeff) Farrow
Mr. Jeffrey S. (Jeff) Farrow
Chief Financial Officer and Chief Strategy Officer
Chief Financial Officer and Chief Strategy Officer
36.70K
+63.63%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Lead Independent Director
Lead Independent Director
13.70K
+32.37%
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
8.70K
+62.62%
Dr. Andrew Goldberg, M.D.
Dr. Andrew Goldberg, M.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth Yeu, M.D.
Dr. Elizabeth Yeu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
151.78K
-16.10%
Dr. Seshadri Neervannan, Ph.D.
Dr. Seshadri Neervannan, Ph.D.
Chief Operating Officer
Chief Operating Officer
79.68K
+23.03%
Dr. Bryan Wahl, M.D., J.D.
Dr. Bryan Wahl, M.D., J.D.
General Counsel, Secretary
General Counsel, Secretary
49.09K
+24.08%
Mr. Aziz Mottiwala
Mr. Aziz Mottiwala
Chief Commercial Officer
Chief Commercial Officer
47.56K
-26.90%
Ms. Dianne C. Whitfield
Ms. Dianne C. Whitfield
Chief Human Resources Officer
Chief Human Resources Officer
44.38K
+37.80%
Mr. Jeffrey S. (Jeff) Farrow
Mr. Jeffrey S. (Jeff) Farrow
Chief Financial Officer and Chief Strategy Officer
Chief Financial Officer and Chief Strategy Officer
36.70K
+63.63%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 24
Updated: Sun, Aug 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
7.37%
Paradigm BioCapital Advisors LP
7.05%
Jennison Associates LLC
5.85%
Tang Capital Management, LLC
5.82%
Other
66.55%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
7.37%
BlackRock Institutional Trust Company, N.A.
7.37%
Paradigm BioCapital Advisors LP
7.05%
Jennison Associates LLC
5.85%
Tang Capital Management, LLC
5.82%
Other
66.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.99%
Investment Advisor/Hedge Fund
34.22%
Hedge Fund
29.24%
Research Firm
9.93%
Private Equity
3.78%
Individual Investor
3.28%
Sovereign Wealth Fund
1.12%
Bank and Trust
0.34%
Pension Fund
0.34%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
402
46.20M
109.45%
-3.88M
2025Q1
407
48.50M
115.53%
-3.34M
2024Q4
378
44.81M
116.78%
-6.00M
2024Q3
339
47.74M
124.97%
+1.40M
2024Q2
315
44.21M
116.20%
+181.38K
2024Q1
291
44.53M
119.96%
+4.60M
2023Q4
241
35.50M
106.12%
-146.85K
2023Q3
226
34.34M
108.40%
+5.84M
2023Q2
202
25.92M
97.99%
-1.52M
2023Q1
186
24.53M
93.13%
-2.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
3.32M
7.89%
+79.48K
+2.46%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
6.74%
-82.65K
-2.84%
Mar 31, 2025
Paradigm BioCapital Advisors LP
2.61M
6.21%
+78.30K
+3.09%
Mar 31, 2025
Jennison Associates LLC
2.49M
5.93%
-7.49K
-0.30%
Mar 31, 2025
Tang Capital Management, LLC
2.45M
5.84%
+200.00K
+8.87%
Mar 31, 2025
Deep Track Capital LP
1.48M
3.53%
+1.48M
--
Mar 31, 2025
The Vanguard Group, Inc.
2.22M
5.28%
+111.43K
+5.28%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.74M
4.15%
+215.40K
+14.10%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.40M
3.33%
-190.00K
-11.97%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
